AlfordDP, ComptonP, SametJH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med, 2006; 144:127–134.
2.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. buprenorphine.samhsa.gov/Bup_Guidelines.pdf. 2009 June 25.
3.
HeitHA, GourlayDL. Buprenorphine: New tricks with an old molecule for pain management. Clin J Pain, 2008; 24:93–97.
4.
HelmS, TrescotAM, ColsonJ, SehgalN, SilvermanS. Opioid antagonists, partial agonists, and agonists/antagonists: The role of office-based detoxification. Pain Physician, 2008; 11:225–235.
KögelB, ChristophT, StrassburgerW, FriderichsE. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain, 2005; 9,5:599–611.
7.
MarkTL, KassedCA, Vandivort-WarrenR, LevitKR, KranzlerHR. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend, 2009; 99:345–349.
8.
MercadanteS, VillariP, FerreraP, PorzioG, AielliF, VernaL, CasuccioA. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage, 2006; 32,2:175–179.
9.
SchumacherMA, BasbaumAI, WayWL. Opioid analgesics and antagonists. KatzungBG. Basic and Clinical Pharmacology. New York: McGraw-Hill, 2007.
